Actinver Wealth Management Inc. acquired a new stake in shares of Metlife Inc (NYSE:MET) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 8,512 shares of the financial services provider’s stock, valued at approximately $468,000.
A number of other large investors also recently modified their holdings of the business. Banced Corp grew its stake in Metlife by 3.0% in the fourth quarter. Banced Corp now owns 8,156 shares of the financial services provider’s stock worth $335,000 after purchasing an additional 236 shares during the period. Wetherby Asset Management Inc. grew its stake in Metlife by 1.6% in the fourth quarter. Wetherby Asset Management Inc. now owns 15,615 shares of the financial services provider’s stock worth $641,000 after purchasing an additional 239 shares during the period. Adirondack Trust Co. grew its stake in Metlife by 3.2% in the fourth quarter. Adirondack Trust Co. now owns 8,196 shares of the financial services provider’s stock worth $337,000 after purchasing an additional 256 shares during the period. Fulton Bank N.A. grew its stake in Metlife by 4.1% in the fourth quarter. Fulton Bank N.A. now owns 6,637 shares of the financial services provider’s stock worth $272,000 after purchasing an additional 262 shares during the period. Finally, San Francisco Sentry Investment Group CA grew its stake in Metlife by 22.5% in the fourth quarter. San Francisco Sentry Investment Group CA now owns 1,433 shares of the financial services provider’s stock worth $59,000 after purchasing an additional 263 shares during the period. Institutional investors and hedge funds own 76.88% of the company’s stock.
In other Metlife news, EVP Steven J. Goulart sold 10,292 shares of the firm’s stock in a transaction that occurred on Tuesday, February 12th. The stock was sold at an average price of $44.40, for a total transaction of $456,964.80. Following the completion of the transaction, the executive vice president now owns 93,214 shares in the company, valued at approximately $4,138,701.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO John D. Mccallion sold 2,669 shares of the firm’s stock in a transaction that occurred on Tuesday, February 12th. The stock was sold at an average price of $44.43, for a total value of $118,583.67. Following the sale, the chief financial officer now directly owns 20,538 shares of the company’s stock, valued at $912,503.34. The disclosure for this sale can be found here. Company insiders own 0.34% of the company’s stock.
Metlife (NYSE:MET) last posted its earnings results on Wednesday, February 6th. The financial services provider reported $1.35 earnings per share for the quarter, beating analysts’ consensus estimates of $1.30 by $0.05. The company had revenue of $15.40 billion for the quarter, compared to the consensus estimate of $15.84 billion. Metlife had a return on equity of 10.24% and a net margin of 7.53%. Metlife’s revenue was up .0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.64 earnings per share. Equities analysts predict that Metlife Inc will post 5.48 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, June 13th. Shareholders of record on Tuesday, May 7th will be given a $0.44 dividend. This is a boost from Metlife’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Monday, May 6th. This represents a $1.76 dividend on an annualized basis and a yield of 3.90%. Metlife’s dividend payout ratio is presently 31.17%.
A number of research firms have recently commented on MET. Bank of America raised Metlife from a “neutral” rating to a “buy” rating and set a $44.06 target price on the stock in a research note on Wednesday, January 16th. Wells Fargo & Co reissued a “buy” rating on shares of Metlife in a research note on Tuesday, January 8th. Sandler O’Neill raised Metlife from a “hold” rating to a “buy” rating in a research note on Wednesday, January 2nd. Argus reissued a “buy” rating on shares of Metlife in a research note on Tuesday, February 12th. Finally, Zacks Investment Research cut Metlife from a “buy” rating to a “hold” rating in a research note on Monday, January 21st. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $52.76.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.baseballdailydigest.com/news/2019/04/26/actinver-wealth-management-inc-acquires-new-stake-in-metlife-inc-met.html.
MetLife, Inc engages in the insurance, annuities, employee benefits, and asset management businesses. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short- and long-term disability, individual disability, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and stable value products, including general and separate account guaranteed interest contracts, and private floating rate funding agreements.
Further Reading: How Do I Invest in Dividend Stocks
Receive News & Ratings for Metlife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metlife and related companies with MarketBeat.com's FREE daily email newsletter.